We are the first company to use CRISPR technology to improve poppy genetics.


With exclusive ownership and production of the P. Bracteatum strain, and the associated innovative technology, we hope to do our part to contribute to an improvement in quality of life.


About Us


Our Mission

Make a difference in the lives of patients and contribute to ending the heroin epidemic by supplying non-addictive pain opiates.

Our Vision
To produce organic and safer pharmaceutical compounds which are non-addictive for pain management and cancer research.



Our Values

PEOPLE.
SUSTAINABILITY.
SUPERIOR QUALITY.
INNOVATION.


We embrace the triple bottom line philosophy of ethics.

We strive to help people by contributing to ending the opioid epidemic.

We honor environmental sustainability without sacrificing quality.

We pride ourselves on the superior value we offer our customers.

Our Team


Led by world-class management with significant experience in plant genomics, drug regulation and agronomy, our team is dedicated to bringing the next generation of pain medication to the market.
Executive Leadership Team

Image
DR. RAJ MADAM

Founder & CEO

Image
DR. MARY COLE
SCIENTIFIC ADVISOR
Image
ALAN COLE
SCIENTIFIC ADVISOR
Image
DOUGLAS BRIEN

DIRECTOR OF OPERATIONS
Australia

Drew Vanderhoff - Emerzene Therapeutics

DREW VANDERHOFF

CHIEF OF INVESTOR RELATIONS

Drew Vanderhoff - Emerzene Therapeutics

Jill Sandnes

Director of Marketing

FAQ


Image

We are actively looking to partner with pharmaceutical companies for our R&D trials to propel the next generation of medicinal advances.


PARTNER WITH US


Image

© 2024 Emerzene. All rights reserved.
Design by Bhakti Creative.